{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Nevi&page=3",
    "query": {
      "condition": "Congenital Nevi",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 93,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Nevi&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Nevi&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T17:33:39.880Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03725449",
      "title": "Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dysplastic Nevus",
        "Health Status Unknown",
        "Melanoma",
        "No Evidence of Disease"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "mySmartCheck",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 116,
      "start_date": "2018-11-03",
      "completion_date": "2020-08-29",
      "has_results": false,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03725449"
    },
    {
      "nct_id": "NCT04320316",
      "title": "A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Epidermal Nevus Syndrome"
      ],
      "interventions": [
        {
          "name": "Crysvita (burosumab-twza) Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "6 Months and older · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2020-07-31",
      "completion_date": "2021-08-31",
      "has_results": true,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04320316"
    },
    {
      "nct_id": "NCT02828111",
      "title": "Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Basal Cell Carcinomas"
      ],
      "interventions": [
        {
          "name": "Patidegib",
          "type": "DRUG"
        },
        {
          "name": "Vehicle gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PellePharm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-11-11",
      "completion_date": "2017-11-09",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02828111"
    },
    {
      "nct_id": "NCT06805825",
      "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumors",
        "Small-cell Lung Cancer",
        "Adenoid Cystic Carcinoma",
        "Uveal Melanoma",
        "Neuroendocrine Tumors",
        "Chromophobe Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "NN3201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novelty Nobility, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2025-02-03",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 5,
      "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06805825"
    },
    {
      "nct_id": "NCT06915441",
      "title": "Lipid Infusions to Optimize Nutrition Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bronchopulmonary Dysplasia",
        "Neurodevelopmental Impairment"
      ],
      "interventions": [
        {
          "name": "SOLE",
          "type": "DRUG"
        },
        {
          "name": "MOLE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Hours",
        "maximum_age": "28 Weeks",
        "sex": "ALL",
        "summary": "12 Hours to 28 Weeks"
      },
      "enrollment_count": 230,
      "start_date": "2026-04-29",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06915441"
    },
    {
      "nct_id": "NCT01556009",
      "title": "Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Basal Cell Nevus Syndrome",
        "Gorlin's Syndrome"
      ],
      "interventions": [
        {
          "name": "Vismodegib",
          "type": "DRUG"
        },
        {
          "name": "Aminolevulinic acid %20 topical solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCSF Benioff Children's Hospital Oakland",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2012-04",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-02",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 3,
      "location_summary": "Oakland, California • New York, New York",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01556009"
    },
    {
      "nct_id": "NCT01942993",
      "title": "The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Philip Friedlander",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2013-09",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2020-09-30",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01942993"
    },
    {
      "nct_id": "NCT06246903",
      "title": "INTER-PATHOLOGIST READER STUDY",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Nevi, Dysplastic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Orlucent, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 500,
      "start_date": "2023-06-15",
      "completion_date": "2024-08-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06246903"
    },
    {
      "nct_id": "NCT06599619",
      "title": "Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Single agent, adjuvant anti-PD1 therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Kirkwood",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-02-20",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06599619"
    },
    {
      "nct_id": "NCT00020267",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Adult Soft Tissue Sarcoma",
        "Colorectal Cancer",
        "Bone Cancer",
        "Ovarian Sarcoma",
        "Melanoma",
        "Colon Cancer",
        "Rectal Cancer",
        "Breast Cancer",
        "Eye Cancer",
        "Uterine Sarcoma"
      ],
      "interventions": [
        {
          "name": "interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "MAGE-12 peptide vaccine",
          "type": "DRUG"
        },
        {
          "name": "Montanide ISA-51",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-10-06T17:33:39.880Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020267"
    }
  ]
}